Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

13 mai 2026 10h00 HE | Source: Oncotelic Therapeutics, Inc.

Sapu Nano Announces First Patient Dosed in Phase 1b Trial of Sapu003, an Intravenous Deciparticle™ Formulation of Everolimus

SAN DIEGO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- via IBN -- Sapu Nano and Oncotelic (OTCQB: OTLC) today announced that the first patient has been dosed in the Phase 1b clinical trial of Sapu003,...
04 déc. 2025 02h57 HE | Source: Sapu Bioscience, LLC

Sapu Nano Announces New PK Data Demonstrating IV Sapu003 Reduces GI Accumulation of Everolimus up to 67-Fold Compared With Oral Dosing

San Diego, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Sapu Nano today announced new pharmacokinetic (PK) and tissue-distribution results demonstrating that Sapu003, the company’s intravenous (IV)...
03 déc. 2025 00h27 HE | Source: Sapu Bioscience, LLC

Sapu Nano Unveils Broad-Applicability Deciparticle™ Nanomedicine Platform Capable of Formulating Multiple Hydrophobic Peptide, Macrolide, and Polyketide Drugs

San Diego, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Sapu Nano, a clinical-stage nanomedicine company, today announced new data demonstrating that its proprietary Deciparticle™ platform enables...
24 sept. 2025 20h00 HE | Source: Sapu Biosciences, LLC

Sapu Nano’s Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients

Sapu003 Designed to Overcome Limitations of Afinitor®, FDA-Approved Oral Everolimus, Delivering Full Strength of Everolimus via Intravenous Injection AUSTRALIA, Sydney, Sept. 24, 2025 (GLOBE...